BP-897 Bioprojet.
BP-897 is a dopamine D3 receptor agonist which is under development by Bioprojet for the potential treatment of drug craving and vulnerability to relapse that are elicited by drug-associated environmental stimuli; it is undergoing phase I trials [318397,334036,340721]. Preclinical investigations were carried out by Cambridge University and INSERM [295680]. BP-897 functions as a partial agonist in vitro and as either an agonist or an antagonist in vivo. It inhibits cocaine-seeking behavior that depends upon the presentation of drug-associated cues, without having any intrinsic, primary rewarding effects [334036]. In preclinical studies, BP-897 administration before testing reduced cocaine-seeking behavior in rats in a dose-dependent manner [304557,307758,334036]. In D3 receptor knockout mice, BP-897 has no effect [345710]. It does not reduce self-administration of cocaine in monkeys [318397].
Preti
A
A
Genneruxi Medical Center, via Costantinopoli 42, I-09129, Cagliari, Italy. apreti@tin.it
D000818:Animals; D002986:Clinical Trials as Topic; D019970:Cocaine-Related Disorders / Q000188:drug therapy* / Q000523:psychology; D000075202:Contraindications; D015507:Drugs, Investigational / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D010879:Piperazines / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D017448:Receptors, Dopamine D2 / Q000187:drug effects; D050637:Receptors, Dopamine D3
C493593:DRD3 protein, human; D015507:Drugs, Investigational; D010879:Piperazines; D011619:Psychotropic Drugs; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; C120565:BP 897